Koers Lonza Group Ltd Other OTC
Aandelen
LZAGY
US54338V1017
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 6,64 mld. 7,22 mld. 6,77 mld. | Omzet 2025 * | 7,44 mld. 8,09 mld. 7,59 mld. | Marktkapitalisatie | 36,81 mld. 40,01 mld. 37,51 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 904 mln. 983 mln. 921 mln. | Nettowinst (verlies) 2025 * | 1,11 mld. 1,21 mld. 1,14 mld. | EV/omzet 2024 * | 5,87 x |
Nettoschuld 2024 * | 2,18 mld. 2,37 mld. 2,22 mld. | Nettoschuld 2025 * | 2,47 mld. 2,68 mld. 2,52 mld. | EV/omzet 2025 * | 5,28 x |
K/w-verhouding 2024 * |
41,3
x | K/w-verhouding 2025 * |
33,1
x | Werknemers | - |
Dividendrendement 2024 * |
0,88% | Dividendrendement 2025 * |
1,01% | Vrij verhandelbaar | 95,87% |
Recentste transcriptie over Lonza Group Ltd
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Albert Baehny
CEO | Chief Executive Officer | 72 | 25-04-17 |
Philippe Deecke
DFI | Director of Finance/CFO | 52 | 01-12-21 |
Maria Nunez
COO | Chief Operating Officer | 55 | 01-08-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Barbara Richmond
BRD | Director/Board Member | 63 | 16-04-14 |
Director/Board Member | 66 | 16-04-14 | |
Marion Helmes
BRD | Director/Board Member | 58 | 05-05-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,17% | 42,86 mld. | |
+10,92% | 42,74 mld. | |
-6,20% | 27,68 mld. | |
+5,23% | 25,15 mld. | |
-24,79% | 18,63 mld. | |
+26,69% | 12,37 mld. | |
-3,13% | 11,92 mld. | |
+6,57% | 11,21 mld. | |
-18,08% | 10,14 mld. |